Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers

Vaccine

Volumn 34, Issue 23, 2016, Pages 2585-2592

  Bézay, Nicole ^a   Ayad, Andrea ^a   Dubischar, Katrin ^a   Firbas, Christa ^b   Hochreiter, Romana ^a   Kiermayr, Sigrid ^a   Kiss, István ^c   Pinl, Fritz ^d   Jilma, Bernd ^b   Westritschnig, Kerstin ^a  

^a Valneva Austria GmbH   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c St Imre Univ Teaching Hospital   (Hungary)

^d Privatklinik Leech   (Austria)

Author keywords

C. difficile; C. difficile associated diarrhoea (CDAD); C. difficile infection (CDI); C. difficile vaccine

Indexed keywords

ALUMINUM POTASSIUM SULFATE; BACTERIAL VACCINE; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; CLOSTRIDIUM DIFFICILE VACCINE; IMMUNOGLOBULIN G ANTIBODY; UNCLASSIFIED DRUG; ALUMINUM SULFATE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BACTERIAL TOXIN; BACTERIUM ANTIBODY; ENTEROTOXIN; IMMUNOLOGICAL ADJUVANT; RECOMBINANT PROTEIN; TCDA PROTEIN, CLOSTRIDIUM DIFFICILE; TOXB PROTEIN, CLOSTRIDIUM DIFFICILE;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNIZATION; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE RASH; INJECTION SITE REACTION; INJECTION SITE SWELLING; LYMPHADENOPATHY; MALE; MYALGIA; NAUSEA; NORMAL HUMAN; OPEN STUDY; PEPTOCLOSTRIDIUM DIFFICILE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; CLOSTRIDIUM INFECTIONS; IMMUNOLOGY; MIDDLE AGED; SECONDARY IMMUNIZATION; SERODIAGNOSIS; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; ALUM COMPOUNDS; ANTI-BACTERIAL AGENTS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL TOXINS; BACTERIAL VACCINES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ENTEROTOXINS; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; RECOMBINANT PROTEINS; YOUNG ADULT;

EID: 84963642757     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.03.098     Document Type: Article

References (21)

1. Leffler D.A., Lamont J.T. Clostridium difficile infection. N Engl J Med 2015, 372:1539-1548.
2. Vaishnavi C. Clinical spectrum & pathogenesis of Clostridium difficile associated diseases. Indian J Med Res 2010, 131:487-499.
3. Bartlett J.G., Moon N., Chang T.W., Tylor N., Onderdonk A.B. Role of Clostridium difficile in antibiotic-associated pseudomembraneous colitis. Gastroenterology 1978, 75:778-782.
4. Magill S.S., Edwards J.R., Bamberg W., Beldavs Z.G., Dumyati G., Kainer M.A., et al. Multistate point-prevalence survey of healthcare-associated infections. N Engl J Med 2014, 370:1198-1208.
5. Lessa F.C., Mu Y., Bamberg W.M., Beldavs Z.G., Dumyati G.K., Dunn J.R., et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015, 372:825-834.
6. Clostridium difficile infection in Europe. A CDI Europe Report, [assessed September 2015]. http://www.multivu.com/assets/60637/documents/60637-CDI-HCP-Report-original.pdf.
7. Kyne L., Warny M., Qamar A., Kelly C.P. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against Toxin A. N Engl J Med 2000, 342:390-397.
8. Kyne L., Warny M., Qamar A., Kelly C.P. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001, 357:189-193.
9. Leav B.A., Blair B., Leney M., Knauber M., Reilly C., Lowy I., et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 2010, 28:965-969.
10. Aronsson B., Granström M., Möllby R., Nord C.E. Serum antibody response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea. Infection 1985, 13(3):97-101.
11. FDA Guidance for Industry: Toxicity Scale for Healthy Adult and Adolescent Subjects Enrolled in Preventive Vaccine Clinical Trials (2007), [assessed December 2015]. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091977.pdf.
12. Study of a Candidate Clostridium difficile Toxoid Vaccine (C. diffense) in Subjects at Risk for C. Difficile Infection, NCT01887912, [assessed September 2015]. https://clinicaltrials.gov/ct2/show/NCT01887912?term=clostridium+difficile+vaccine+sanofi%26rank=2.
13. Study To Investigate Two 3-dose Schedules Of A Clostridium difficile Vaccine In Healthy Adults Aged 65 to 85 Years, NCT02561195, [assessed September 2015]. https://clinicaltrials.gov/ct2/show/NCT02561195?term=clostridium+difficile+vaccine+pfizer%26rank=1.
14. Tian J.H., Fuhrmann S.R., Kluepfel-Stahl S., Carman R.J., Ellingsworth L., Flyer D.C. A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models. Vaccine 2012, 30:4249-4258.
15. ®, IC51, in elderly. Data Presented at the 13th CISTM 2015, Abstract PO14.04, available at http://www.istm.org/Files/Documents/Activities/Meetings/Congresses/CISTM13/Abstracts-PosterPresentations.pdf [assessed September 2015].
16. ® (IC51), in 6 months of follow-up. Vaccine 2010, 28:6463-6469.
17. Westritschnig K., Hochreiter R., Wallner G., Firbas C., Schwameis M., Jilma B. A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers. Hum Vaccin Immunother 2014, 10(1):170-183.
18. Wressnigg N., Pöllabauer E.M., Aichinger G., Portsmouth D., Löw-Baselli A., Fritsch S., et al. Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomized, dose-escalation phase 1/2 trial. Lancet Infect Dis 2013, 13:680-689.
19. Greenberg R.N., Marbury T.C., Foglia G., Warny M. Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine. Vaccine 2012, 30:2245-2249.
20. Foglia G., Shah S., Luxemburger C., Pietrobon P.J.F. Clostridium difficile: development of a novel candidate vaccine. Vaccine 2012, 30:4307-4309.
21. Solomon K., Martin A.J., O'Donoghue C., Chen X., Fenelon L., Fanning S., et al. Mortality in patients with Clostridium difficile infection correlates with host pro-inflammatory and humoral immune responses. J Med Microbiol 2013, 62:1453-1460.